UY33369A - Heterociclilbencil-pirazoles sustituidos y su uso - Google Patents

Heterociclilbencil-pirazoles sustituidos y su uso

Info

Publication number
UY33369A
UY33369A UY0001033369A UY33369A UY33369A UY 33369 A UY33369 A UY 33369A UY 0001033369 A UY0001033369 A UY 0001033369A UY 33369 A UY33369 A UY 33369A UY 33369 A UY33369 A UY 33369A
Authority
UY
Uruguay
Prior art keywords
diseases
prevention
treatment
heterociclilbencil
pirazoles
Prior art date
Application number
UY0001033369A
Other languages
English (en)
Inventor
Dr Hartmut Beck
Haerter Dr Michael
Greschat Dr Susanne
Dr Peter Ellinghaus
Dr Kerstin Berhoerster
Dr Joachin Schumacher
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44063276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33369(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY33369A publication Critical patent/UY33369A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente solicitud se refiere a nuevos derivados de 1-[3-5 (heterociclil)bencil]-1 H-pirazol sustituidos, a procedimientos para su preparacion, a su use para el tratamiento y/o la prevencion de enfermedades, asi como a su use para la preparacion de farmacos para el tratamiento y/o la prevencion de enfermedades, especialmente para el tratamiento y/o la prevencion de enfermedades hiperproliferativas y angiogenicas, asi como a aquellas enfermedades que aparecen debido a una adaptacion metabolica a estados hipoxicos . Tales tratamientos pueden realizarse como monoterapia o tambien en combinacion con otros farmacos u otras medidas terapeuticas.
UY0001033369A 2010-05-08 2011-05-04 Heterociclilbencil-pirazoles sustituidos y su uso UY33369A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10004855 2010-05-08

Publications (1)

Publication Number Publication Date
UY33369A true UY33369A (es) 2011-12-01

Family

ID=44063276

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033369A UY33369A (es) 2010-05-08 2011-05-04 Heterociclilbencil-pirazoles sustituidos y su uso

Country Status (25)

Country Link
US (2) US20130172311A1 (es)
EP (1) EP2569312B1 (es)
JP (1) JP5727002B2 (es)
KR (1) KR20130108997A (es)
CN (1) CN103003269B (es)
AR (1) AR081368A1 (es)
AU (1) AU2011252223A1 (es)
BR (1) BR112012028651A2 (es)
CA (1) CA2798375A1 (es)
CO (1) CO6640218A2 (es)
CR (1) CR20120570A (es)
CU (1) CU20120157A7 (es)
DO (1) DOP2012000284A (es)
EA (1) EA201291167A1 (es)
EC (1) ECSP12012288A (es)
ES (1) ES2462522T3 (es)
IL (1) IL222851A0 (es)
MA (1) MA34939B1 (es)
MX (1) MX2012012960A (es)
PE (1) PE20130228A1 (es)
SG (1) SG185459A1 (es)
TN (1) TN2012000531A1 (es)
TW (1) TW201200510A (es)
UY (1) UY33369A (es)
WO (1) WO2011141326A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101688247A (zh) * 2007-05-01 2010-03-31 希尔氏宠物营养品公司 猫科动物骨关节炎的诊断方法和组合物
CA2687306A1 (en) * 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
BR112012028651A2 (pt) * 2010-05-08 2016-08-09 Bayer Ip Gmbh heterociclilbenzilpirazóis substituídos e uso do mesmo
CA2876215A1 (en) 2012-07-02 2014-01-09 Monsanto Technology Llc Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
US9115120B2 (en) 2012-08-24 2015-08-25 Board Of Regents, The University Of Texas Systems Heterocyclic modulators of HIF activity for treatment of disease
EP2888256A4 (en) * 2012-08-24 2016-02-17 Univ Texas HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES
NZ704799A (en) 2012-08-24 2018-06-29 Univ Texas Heterocyclic modulators of hif activity for treatment of disease
DK3110420T3 (da) 2014-02-25 2019-05-13 Board Of Regents Univ Of Texas System Salte af heterocykliske modulatorer af hif-aktivitet til behandling af sygdomme
US10191597B2 (en) 2015-06-30 2019-01-29 Synaptics Incorporated Modulating a reference voltage to preform capacitive sensing
CN110167916B (zh) * 2017-01-13 2022-11-11 日产化学株式会社 芳香族二胺化合物前体的制造方法
CN115944626B (zh) * 2022-12-08 2024-04-19 桂林医学院附属医院 小分子化合物在制备抗缺氧或缺血再灌注损伤药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610726B2 (en) * 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
EP1613614A2 (en) 2003-04-03 2006-01-11 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
EP1646382A4 (en) 2003-06-30 2010-07-21 Hif Bio Inc COMPOUNDS, COMPOSITIONS AND METHODS
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
CA2687306A1 (en) * 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
DE102008057344A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
BRPI0921257A2 (pt) * 2008-11-14 2016-02-23 Bayer Schering Pharma Ag composto de arila heterociclicamente subsittuidos como inibidores hif
KR20110082570A (ko) * 2008-11-14 2011-07-19 바이엘 쉐링 파마 악티엔게젤샤프트 Ｈｉｆ 억제제로서 사용하기 위한 헤테로방향족 화합물
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
JP2012515789A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー スフィンゴシン−１−リン酸アゴニストとしてのピラゾール−１，２，４−オキサジアゾール誘導体
BR112012028651A2 (pt) * 2010-05-08 2016-08-09 Bayer Ip Gmbh heterociclilbenzilpirazóis substituídos e uso do mesmo

Also Published As

Publication number Publication date
CR20120570A (es) 2013-04-22
KR20130108997A (ko) 2013-10-07
TW201200510A (en) 2012-01-01
AU2011252223A1 (en) 2012-12-06
WO2011141326A1 (de) 2011-11-17
CN103003269A (zh) 2013-03-27
TN2012000531A1 (en) 2014-04-01
CA2798375A1 (en) 2011-11-17
ES2462522T3 (es) 2014-05-23
JP2013526497A (ja) 2013-06-24
JP5727002B2 (ja) 2015-06-03
DOP2012000284A (es) 2013-03-31
ECSP12012288A (es) 2012-12-28
US20120028950A1 (en) 2012-02-02
MX2012012960A (es) 2012-12-17
PE20130228A1 (es) 2013-03-15
IL222851A0 (en) 2012-12-31
EA201291167A1 (ru) 2013-05-30
CO6640218A2 (es) 2013-03-22
US8470811B2 (en) 2013-06-25
CU20120157A7 (es) 2013-03-27
AR081368A1 (es) 2012-08-29
EP2569312A1 (de) 2013-03-20
CN103003269B (zh) 2015-11-25
SG185459A1 (en) 2012-12-28
EP2569312B1 (de) 2014-03-26
MA34939B1 (fr) 2014-03-01
US20130172311A1 (en) 2013-07-04
BR112012028651A2 (pt) 2016-08-09

Similar Documents

Publication Publication Date Title
UY33369A (es) Heterociclilbencil-pirazoles sustituidos y su uso
SV2011003901A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
GT201500105A (es) Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso
UY32236A (es) Compuestos de arilo sustituidos y su uso
PL3517539T3 (pl) Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
GT201300235A (es) Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas
NZ719520A (en) Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
CL2013000735A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
CU20140096A7 (es) Fenilimidazopirazoles sustituidos y su uso
EP3980017A4 (en) Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
CO6731081A2 (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
BR112013024606A2 (pt) composição, kit farmacêutico, e, métodos para o tratamento de uma condição de pele, e para preparar uma composição
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
MX2012012905A (es) Hidroxialquilbencilpirazoles y su uso para tratamiento de enfermedades hiperproliferativas y angiogenicas.
WO2010041140A3 (en) Treatment of proliferative disorders with a death receptor agonist
CR20120617A (es) Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso
WO2015015509A3 (en) Ulmoside-a: useful for prevention or cure of metabolic diseases
CL2010001615A1 (es) Uso de eufol en el tratamiento de la inflamacion y el dolor neuropatico.
UA33101U (ru) Устройство для пункции и санации абсцессов легких

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200626